ERBB2 and non-small cell lung carcinoma: This study was followed by the DESTINY-Lung02 trial, which was performed to compare clinical benefits of TDXd with 5.4 mg/kg versus 6.4 mg/kg dosing in patients with advanced NSCLC and HER2 mutations.